Palm Tree Psychological Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 410 S Sherman St, Fitzgerald, GA 31750 Phone: 229-426-0002 |
Georgia Interventions & Family Services, Llc Counselor Medicare: Not Enrolled in Medicare Practice Location: 115 S Sherman St, Fitzgerald, GA 31750 Phone: 229-457-7205 |
Dorminy Medical Center Hospital Units - Psychiatric Unit Medicare: Medicare Enrolled Practice Location: 200 Perry House Rd, Fitzgerald, GA 31750 Phone: 229-424-7100 Fax: 229-424-7281 |
Flat Foot Educational And Disability Services Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 415 N Hooker St, Fitzgerald, GA 31750 Phone: 470-364-8088 |
Gips Counselor Medicare: Not Enrolled in Medicare Practice Location: 201 E Ohoopee St, Fitzgerald, GA 31750 Phone: 229-424-7000 Fax: 229-424-7074 |
News Archive
It's known that many patients die in the months and years after sepsis. But no one has known if this increased risk of death (in the 30 days to 2 years after sepsis) is because of sepsis itself, or because of the pre-existing health conditions the patient had before acquiring the complication.
Burnham Institute for Medical Research (Burnham) announced today that philanthropist T. Denny Sanford has pledged $50 million to support and further expand and accelerate the Institute's leading-edge medical research. To honor Sanford, Burnham, has been renamed the Sanford-Burnham Medical Research Institute. This is the second gift Sanford has made to Burnham. In 2007, he directed $20 million through Sanford Health to create the Sanford Children's Health Research Center at Burnham.
The nation's current healthcare crisis has added a new dimension to the old saying, "Prevention is the best medicine." With rising co-pays, high deductibles, confusion over coverage, and prescription drug headaches, healthcare consumers recognize that getting sick is more complicated than ever.
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced positive preclinical results for CTX-0294945 as an adjuvant therapy to the cancer drug Avastin (bevacizumab - Genentech/Roche). The data is presented today in a late breaking poster at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA.
› Verified 3 days ago